Skip to main content

Parmar Kush's Form 4 filing

Entrada Therapeutics, Inc. (TRDA) · filed Jul 1, 2025

Accession no.
0001415889-25-018824
Filed
Jul 1, 2025
Trade date
Jun 27-Jul 1, 2025
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 6 non-derivative transactions and 0 derivative transactions. Open-market sales total $866.5K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Parmar KushCIK 0001664281Director, 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 27, 2025Common StockSSaleDisposed−55,735$6.91−$385,128.853,220,287Indirect
Jun 27, 2025Common StockSSaleDisposed−19,265$6.91−$133,121.151,113,092Indirect
Jun 30, 2025Common StockSSaleDisposed−18,578$6.81−$126,516.183,201,709Indirect
Jun 30, 2025Common StockSSaleDisposed−6,422$6.81−$43,733.821,106,670Indirect
Jul 1, 2025Common StockSSaleDisposed−18,578$7.12−$132,275.363,183,131Indirect
Jul 1, 2025Common StockSSaleDisposed−6,422$7.12−$45,724.641,100,248Indirect

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)